Mersana Therapeutics Reports Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study
- Maintained 34% objective response rate and 79% disease control rate, including two complete responses - XMT-1536 continues to be generally well-tolerated with no new safety signals - Data to be presented and discussed during a conference call today at 8 …